Liquidia (NASDAQ:LQDA) Insider Scott Moomaw Sells 8,863 Shares of Company Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 8,863 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $252,418.24. Following the sale, the insider owned 181,487 shares in the company, valued at approximately $5,168,749.76. The trade was a 4.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Down 3.1%

Shares of LQDA stock opened at $26.81 on Wednesday. The stock’s 50-day simple moving average is $63.40 and its 200-day simple moving average is $61.76. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The firm has a market capitalization of $2.40 billion, a PE ratio of 19.57 and a beta of 0.61. Liquidia Corporation has a fifty-two week low of $21.94 and a fifty-two week high of $93.61.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The firm had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter in the previous year, the business earned ($0.49) earnings per share. The company’s revenue for the quarter was up 1842.1% compared to the same quarter last year. Equities analysts expect that Liquidia Corporation will post 2.05 earnings per share for the current year.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company boosted its stake in shares of Liquidia by 63.3% in the first quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock worth $2,199,000 after buying an additional 22,592 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Liquidia during the second quarter valued at approximately $29,694,000. Seven Fleet Capital Management LP raised its position in Liquidia by 25.2% during the second quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock valued at $20,459,000 after acquiring an additional 51,727 shares in the last quarter. Bank of America Corp DE raised its position in Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after acquiring an additional 360,372 shares in the last quarter. Finally, Handelsbanken Fonder AB purchased a new position in Liquidia during the second quarter valued at approximately $1,993,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on LQDA. Stephens set a $130.00 price target on shares of Liquidia in a research report on Friday, July 24th. Lifesci Capital downgraded shares of Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price objective on the stock. in a report on Wednesday, August 12th. Jefferies Financial Group raised shares of Liquidia to a “strong-buy” rating in a report on Thursday, October 1st. Zacks Research lowered shares of Liquidia from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 22nd. Finally, HC Wainwright reduced their target price on shares of Liquidia from $130.00 to $58.00 and set a “buy” rating for the company in a report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $83.69.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).